Open an account

IMAC Holdings

BACK · OTC

$0.0001+$0.0004 (−133.33%)TodayMarket closed ·
No price history for this range.

About BACK

IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. The company is headquartered in Franklin, Tennessee and currently employs 15 full-time employees. The company went IPO on 2019-02-13. The Company, through its subsidiary, Ignite Proteomics LLC (Ignite Proteomics), leverages its multi-analyte proteomic assay to help oncologists pinpoint the effective targeted therapies for each patient. Its product is a patented Reverse Phase Protein Array (RPPA) technology platform, which can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. Ignite Proteomics operates a CLIA-certified and CAP-accredited laboratory and offers single-gene tests by evaluating entire protein pathways in cancer cells. Its commercially available lab developed test (LDT), the Ignite RPPA Assay for Breast Cancer, is being utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.

Employees
15
Headquarters
Franklin, Tennessee
Listed
Feb 13, 2019
Sector
Health Care
Industry
Biotechnology
Website
imacregeneration.com

BACK key statistics

Market cap
378
Price-earnings ratio
0.00
Dividend yield
—
Average volume
227
Volume
20
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.21
52 Week low
$0.0001

IMAC Holdings (BACK) at a glance

IMAC Holdings (BACK) last traded at $0.0001, with a market cap of 378 and a price-to-earnings ratio of 0.00.

Volume so far is 20 shares, below the average of 227 shares a day.

Over the past year IMAC Holdings has ranged from $0.0001 to $0.21, and now sits 0% of the way up that range.

IMAC Holdings met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q3 FY24 it reported -$1.38 per share against an estimate of -$0.8874.

BACK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 62.3% on average.

  1. Q4 FY22: reported -$6.90 per share against an estimate of -$2.14
  2. Q1 FY23: reported -$3.30 per share against an estimate of -$1.53
  3. Q2 FY23: reported -$1.20 per share against an estimate of -$0.918
  4. Q3 FY23: reported -$2.63 per share against an estimate of -$0.612
  5. Q4 FY23: reported -$1.31 per share against an estimate of -$0.7446
  6. Q1 FY24: reported -$0.35 per share against an estimate of -$0.9282
  7. Q2 FY24: reported -$1.72 per share against an estimate of -$0.4488
  8. Q3 FY24: reported -$1.38 per share against an estimate of -$0.8874

BACK news

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Avi Kapoor

    US Stocks Mixed; General Dynamics Earnings Top Views

  • Avi Kapoor

    Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

  • Market-Moving News for January 28th

  • Rishabh Mishra

    US Stocks Futures Trade Higher A Day After A Rout In Nvidia And Other Tech Stocks: Investors Brace For Fed Decision, Big Tech Earnings

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

Similar companies

Companies in the same industry as IMAC Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.